Web Analytics
หุ้น OGN (NYSE) | ORGANON & CO – วิเคราะห์โดย Deepscope
MARKET

Select Market Data Region

OGN — ORGANON & CO (Healthcare >> Drug Manufacturers - General)

OGN FAQ

What is OGN's P/E ratio?

ORGANON & CO (OGN) currently trades at a P/E ratio of 7.78.

What is OGN's ROE?

ORGANON & CO reports a Return on Equity (ROE) of 27.24%.

What is OGN's dividend yield?

ORGANON & CO offers a dividend yield of 0.60%.

What is OGN's Deepscope Quality Score?

Deepscope rates OGN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OGN?

Deepscope's AI Timing Score for OGN is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OGN belong to?

ORGANON & CO is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.

Stock Check   *ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.*
(Price: 2026-06-08 | FS: 2026-03-31)

USD 13.39
0.03 (0.22%) Day Change
7.78
P/E
9.49
D/E
27.2%
ROE
1.9%
ROA
0.60%
Div Yield
-0.28
PEG
USD 13.39
Price
0.03 (0.22%)
Day Change
NEWS SCORE: 89

OGN มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 38) แต่ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

38

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ในปีก่อน เป็นลบ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำเมื่อเทียบกับอัตราผลตอบแทนผู้ถือหุ้น(ROE)
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตราการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ในปีก่อน ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ยังไม่ดีนัก สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ยังไม่ดีนัก , ...

ปัจจัยทางคุณภาพ 51%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 89
  Magic Formula Rank by ROA
1467
  Magic Formula Rank by ROE
1467
  Magic Formula Rank by ROIC
668
  Price 13.39
  PBV / Sector
3.89 / 2.88
  Earning Per Share 0.94
  PE / Sector
7.78 / 24.66
GREAT
  PEG or PE/Growth / Sector
-0.28 / 0.08
  Average 1M Daily Value
39.50 M
GREAT
  Average 1W Daily Value
28.55 M
GREAT
ปัจจัยทางเทคนิค 71%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
สุขภาพทางการเงิน 41%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
ประสิทธิภาพการทำกำไร 58%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
3.99 / 18.17
  NPM Average (%) / Sector
10.34 / 17.77
GOOD
  NPM Change Average (%) / Sector
-13.11 / 93.90
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
1.89 / 8.90
  ROA Average (%) / Sector
5.36 / 8.60
  ROA Change Average (%) / Sector
-17.16 / 95.12
  ROE (%) / Sector
27.24 / 27.16
GOOD
  ROE Average (%) / Sector
-265.81 / 13.13
  ROE Change Average (%) / Sector
283.05 / 97.95
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
ผลตอบแทนต่อผู้ถือหุ้น 41%
X
  Dividend (%) / Sector
0.60 / 2.53
  Dividend Average (%) / Sector
5.24 / 3.41
GREAT
  Dividend Change Average (%) / Sector
-13.15 / 1.43
รายละเอียดการจดทะเบียน
X
  Analyze Date 2026-06-09 09:39:30
  Symbol OGN
  Name ORGANON & CO
  Sector Healthcare >> Drug Manufacturers - General
  Market NYSE
  Listed Shares 262.60 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 3,508.35 / 243,244.49
ข่าว, ประมาณการ, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 30 Hudson Street, Jersey City, NJ, United States, 07302

Phone: 551 430 6900

Website: https://www.organon.com

Employees: 10,000

Sector: Healthcare >> Drug Manufacturers - General

Description: Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

ME vs SECTOR Healthcare >> Drug Manufacturers - General

OGN (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
OGN
OGN
USD 13.39 (0.22%)
+ Watch + Port Chart